Cocrystal Pharma (COCP) AI Stock Analysis

• Market Cap: $14.15M
• Dividend Yield: N/A
• Average Volume (3M): 16.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: N/A
• EPS Growth: 9.46%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -1.72
• Shares Outstanding: 10,173,790
• 10 Day Avg. Volume: 13,163
• 30 Day Avg. Volume: 16,598
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 584.93% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Cocrystal Pharma's financial challenges, including zero revenue and ongoing losses, heavily weigh down its stock score. Technical indicators are bearish, and the negative P/E ratio further reflects valuation concerns. While the new equity incentive plan is a positive corporate event, it does not substantially improve the outlook given the financial and technical pressures.

Positive Factors

Clinical Trial Progress

CDI-988 yields additional positive Phase 1 data.

Influenza Drug Efficacy

Cocrystal has announced that studies of its influenza drug, CC-42344, have shown efficacy against the new avian influenza strain H5N1.

Safety and Tolerability

Cocrystal Pharma announced favorable safety and tolerability results at dosage levels of up to 800mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-988.

Vaccine Development

The binding site for CC-42344 was not changed and can block reproduction of the new strain, making it an effective vaccine against the virus.

Negative Factors

Data Analysis Challenges

The low infectivity in this study hindered antiviral data analysis.

Cocrystal Pharma Business Overview & Revenue Model

Company Description

Cocrystal Pharma, Inc. (COCP) is a biotechnology company focused on the discovery and development of novel antiviral therapeutics that target serious and chronic viral diseases. The company utilizes its proprietary structure-based drug discovery technology to create innovative solutions for viral infections, including influenza, hepatitis C, and coronaviruses. Cocrystal Pharma operates within the pharmaceutical sector, with core products in various stages of development aiming to address unmet medical needs in the antiviral space.

How the Company Makes Money

Cocrystal Pharma generates revenue primarily through collaborative agreements, licensing deals, and research and development contracts with other pharmaceutical companies. These partnerships often include upfront payments, milestone payments, and royalties based on the successful development and commercialization of targeted antiviral therapies. The company's revenue streams are significantly influenced by its ability to advance its drug candidates through clinical trials and secure strategic partnerships that leverage its proprietary drug discovery technology. Additionally, government grants or funding related to its research areas may also contribute to its financials, although this is less consistent compared to contractual collaborations.

Cocrystal Pharma Financial Statement Overview

Summary

Cocrystal Pharma operates in a challenging financial environment marked by persistent losses and negative cash flows. Although the company maintains a strong equity foundation and low leverage, its ability to generate revenue and manage cash effectively remains weak. Strategic improvements are necessary to address operational inefficiencies and improve financial stability.

Income Statement

Cocrystal Pharma shows a challenging financial position with negative net and gross profit margins over recent periods. The company recorded a negative revenue growth rate since revenue has significantly decreased in recent years. Both EBIT and EBITDA margins are negative, indicating ongoing operational losses and inefficiencies.

Balance Sheet

The balance sheet indicates a strong equity position with minimal debt, as evidenced by a low debt-to-equity ratio. However, the low return on equity and declining total assets suggest inefficient asset utilization and potential liquidity challenges. The equity ratio remains strong, indicating a stable capital structure.

Cash Flow

The cash flow statement reveals negative free cash flow with a declining trend, indicating potential cash availability issues. Operating cash flow is consistently negative, which further stresses cash management. The operating cash flow to net income and free cash flow to net income ratios demonstrate challenges in converting income into cash.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
144.00K	0.00	0.00	0.00	2.01M	6.56M
	Gross Profit
4.00K	-15.17M	-241.60K	-239.50K	1.78M	6.56M
	EBIT
-20.31M	-18.56M	-38.83M	-14.22M	-9.59M	-48.41M
	EBITDA
-18.95M	-19.37M	-38.45M	-13.80M	-9.30M	-47.90M
	Net Income Common Stockholders
-18.70M	-17.98M	-38.84M	-14.19M	-9.66M	-48.19M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
36.49K	26.35M	37.14M	58.70M	33.01M	7.42M
	Total Assets
104.70K	31.26M	40.84M	79.39M	54.24M	28.53M
	Total Debt
0.00	1.85M	297.00K	534.00K	596.00K	817.00K
	Net Debt
-36.49K	-24.50M	-36.85M	-58.17M	-32.41M	-6.60M
	Total Liabilities
53.31K	4.88M	1.27M	1.84M	1.74M	2.82M
	Stockholders Equity
54.23K	26.38M	39.57M	77.55M	52.51M	25.71M
Cash Flow		Free Cash Flow
-11.74M	-14.78M	-21.51M	-12.77M	-10.07M	-1.71M
	Operating Cash Flow
-16.19M	-14.67M	-21.43M	-12.72M	-9.83M	-1.56M
	Investing Cash Flow
-57.01K	-118.00K	-74.00K	-52.00K	-240.00K	-145.00K
	Financing Cash Flow
-174.37K	3.99M	-27.00K	38.47M	35.66M	6.42M

Cocrystal Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COCP, the sentiment is Neutral. The current price of 1.46 is above the 20-day moving average (MA) of 1.35, below the 50-day MA of 1.57, and below the 200-day MA of 1.88, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 53.18 is Neutral, neither overbought nor oversold. The STOCH value of 84.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COCP.

Cocrystal Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%
COCP	43 Neutral	$14.15M	―	-97.50%	―	―	9.46%
PHGE	42 Neutral	$13.96M	―	-189.64%	―	―	45.24%
CRIS	41 Neutral	$14.96M	―	-634.71%	―	8.83%	22.06%
MEIP	41 Neutral	$13.19M	―	-93.69%	―	-100.00%	-292.59%
CLRB	34 Underperform	$14.42M	―	-4693.38%	―	―	56.38%

Cocrystal Pharma Corporate Events

Cocrystal Pharma Presents to Investment Community

On April 23, 2025, Cocrystal Pharma, Inc. presented to members of the investment community. The presentation’s content is not considered filed under the Securities Exchange Act of 1934, indicating it may not impact the company’s legal obligations under this act.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.

Cocrystal Pharma’s financial challenges, including zero revenue and ongoing losses, heavily weigh down its stock score. Technical indicators are bearish, and the negative P/E ratio further reflects valuation concerns. While the new equity incentive plan is a positive corporate event, it does not substantially improve the outlook given the financial and technical pressures.

To see Spark’s full report on COCP stock, click here.

Cocrystal Pharma Approves 2025 Equity Incentive Plan

Cocrystal Pharma, Inc.’s Board of Directors approved the 2025 Equity Incentive Plan on April 2, 2025, with an effective date of March 31, 2025. The plan, subject to shareholder approval, aims to authorize up to 1,500,000 shares of common stock for issuance, with annual increases, to incentivize employees, consultants, officers, and directors. This strategic move is designed to foster company growth by aligning the interests of key personnel with the company’s prosperity, potentially enhancing its market position and attractiveness to talented individuals.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.

Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses impacting its financial health. Technical indicators are bearish, suggesting the stock may continue to face downward pressure. While the recent positive Phase 1 study results offer some potential, the overall financial and market conditions present substantial risks.

To see Spark’s full report on COCP stock, click here.